Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7167518 | 1.00 | MEN1 (0.51) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL19172281 | 0.98 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2744005 | 0.98 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL29125008 | 0.98 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL203262 | 0.98 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23015072 | 0.98 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2786532 | 0.98 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1069647 | 0.98 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1008189 | 0.98 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL30954764 | 0.98 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737443-A1 | SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Tanabe Pharma Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-03-05 | — | — | US | disclosed |
| US-20250354079-A1 | FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM AND MAGNETIC RECORDING MEDIUM | RESONAC CORPORATION (JP) | 2025-11-20 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4626548-A1 | NON PEPTIDERGIC AGONISTS OF OXYTOCIN RECEPTOR | Université de Strasbourg (FR) | 2025-10-08 | — | — | EP | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250195464-A1 | ALOTAKETAL COMPOUNDS AND DERIVATIVES THEREOF FOR USE AS ANTIVIRAL AGENTS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-06-19 | — | — | US | disclosed |
| EP-4543893-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AND CONJUGATES FOR THE TREATMENT OF CANCER | Evexta Bio (FR) | 2025-04-30 | — | — | EP | disclosed |
| US-3993687-A | ANTIULCER, INHIBITION OF PLATELET AGGREGATION | THE UPJOHN COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
| US-3988361-A | HYPOTENSIVE AGENTS, ANTILIPOLYTIC AGENTS; PROSTAGLANDIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
| US-3987083-A | ANTIULCER, ANTICOAGULANTS, ABORTION, DECONGESTANTS | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3983153-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3983154-A | Racemic prostaglandins of the 2-series and analogs thereof | THE UPJOHN COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3983155-A | Racemic prostaglandins of the 2-series and analogs thereof | THE UPJOHN COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
| US-3981880-A | ANTIULCER, ANTICOAGULANT, WOUND HEALING, ABORTION | THE UPJOHN COMPANY (US) | 1976-09-21 | — | — | US | disclosed |
| US-3980691-A | ANTIULCER, INHIBITION OF PLATELET AGGRESSION, INCREASE OF NASAL PATENCY, ABORTION, WOUND HEALING | THE UPJOHN COMPANY (US) | 1976-09-14 | — | — | US | disclosed |
| US-3974200-A | ANTIULCER, INHIBIT PLATELET AGGREGATION, NASAL PATENCY, ABORTION, WOUND HEALING | THE UPJOHN COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
| US-3959346-A | Racemic prostaglandins of the 2-series and analogs thereof | THE UPJOHN COMPANY (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885KDM4C 293/4885 |
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | SIK1, SIK3, SIK2 | MEN1 3747/4885KMT2A 1971/4885KDM4C 2173/4885 |
| US-20250195464-A1 | ALOTAKETAL COMPOUNDS AND DERIVATIVES THEREOF FOR USE AS ANTIVIRAL AGENTS | SARS1, ACE, ACE2 | MEN1 3964/4885KMT2A 3012/4885KDM4C 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.